case_images: PMC5828565_01
case_images: The results of next generation sequencing in blood sample. (a) Total coverage of Klebsiella pneumoniae in blood sample. (b) Klebsiella pneumoniae genome concordance.
case_images: CRIID2018-3295605.001.jpg
case_images: PMC5828565_01_CRIID2018-3295605.001.jpg
case_images: fig1
case_images: Klebsiella pneumoniae was detected in blood sample with low coverage (0.047%) and depth (Figure 1(a)). Klebsiella pneumoniae genome concordance was 97% (Figure 1(b)).
case_images: The results of synergy susceptibility testing. (a) Synergy susceptibility testing represented synergism between imipenem and ceftazidime (red square). CR-Kp was resistant to imipenem (blue square). (b) No synergism between imipenem and clavulanic acid (yellow square). CR-Kp was resistant to imipenem (blue square). CAZ, ceftazidime; IPM, imipenem; CLA, clavulanic acid.
case_images: CRIID2018-3295605.002.jpg
case_images: PMC5828565_01_CRIID2018-3295605.002.jpg
case_images: fig2
case_images: We performed a synergy susceptibility testing based on large doses of ceftazidime-clavaminic acid and found that it represented synergism between imipenem and ceftazidime (Figures 2(a) and 2(b)).